DEALS: Solvay, Merck Serono ink deals with Gene Logic
Solvay, Merck Serono ink deals with Gene Logic
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Invus |
Lexicon Pharmaceuticals |
$550 investment |
Lexicon will use the money to finance its 10 to 10 program, which has the goal of advancing 10 drug candidates into human clinical trials by 2010. |
|
MGI Pharma |
AkaRx |
$255M deal |
MGI Pharma has shelled out $45 million as a down payment for AkaRx's Phase II therapy for thrombocytopenia. |
|
Pfizer |
Xoma |
$30M licensing pact |
Pfizer has licensed Xoma's tech for screening and manufacturing antibody products for $30 million upfront and a schedule of royalties and milestones. |
|
Merck Serono |
Gene Logic |
Development pact |
The companies will seek alternative development paths for several Merck Serono drug candidates which have been discontinued or de-prioritized. |
|
Solvay |
Gene Logic |
Development deal |
Gene Logic will take a second look at drugs Solvay either discontinued or chose not to prioritize. |
|
Abraxis BioScience |
The Scripps Research Institute |
Licensing agreement |
Abraxis and Scripps have inked an exclusive licensing agreement for the worldwide development and commercialization of a novel epothilone therapeutic for the treatment of cancer. |
Be the first to comment Rate it:
More stories about Pfizer drug candidates development pact MGI Pharma Solvay Merck Serono Gene Logic Lexicon Xoma thrombocytopenia AkaRx
Comments
Post new comment
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends